Meeting
2019 Gastrointestinal Cancers Symposium
Validation of cost-effectiveness of trifluridine/tipiracil versus best supportive care and regorafenib for previously treated metastatic colorectal cancer in the UK using phase IIIb PRECONNECT early access clinical trial data in the real world setting.
Authors
Javier Sabater
Global Market Access, Paris, France
Javier Sabater , Lewis Ralph , Rachael Batteson , Grant McCarthy , Jaro Wex , Shanti Ricardo Moreno Vera , Martin Becquart , Nadjat Mounedji , Julien Taieb , Marc Peeters , Alfredo Falcone
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT03306394
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 639)
DOI
10.1200/JCO.2019.37.4_suppl.639
Abstract #
639
Poster Bd #
L4
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Patient-reported quality of life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: Interim results of the TALLISUR study.
First Author: Meinolf Karthaus
Poster
2019 Gastrointestinal Cancers Symposium
Evaluation of health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC): A prospective, multicenter, open-label, double-arm trial of trifluridine/tipiracil (FTD/TPI) versus best supportive care (BSC).
First Author: Meinolf Karthaus
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated MSS/MSI-low metastatic colorectal cancer (mCRC): The randomized phase 3 STELLAR-303 study.
First Author: Anwaar Saeed
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world treatment patterns and unmet need in patients with previously treated metastatic colorectal cancer that is not MSI-H or dMMR.
First Author: Kaushal Desai